Dysfunctional Uterine Bleeding Market Research Report Information: By Type (Ovulatory), Diagnosis (Hysteroscopy, Ultrasonography), Treatment (Pharmacologic Treatment, Hysterectomy, Endometrial Ablation), End User (Diagnostic Centers) - Forecast Till 2030

Dysfunctional Uterine Bleeding Market Overview

The dysfunctional uterine bleeding market is expected to to reach USD 5,389.76 Million by 2030 at CAGR of 7.20% during the forecast 2020-2030. Dysfunctional uterine bleeding, also known as abnormal uterine bleeding, is irregular bleeding occurring in the absence of any recognizable pelvic pathology. Pregnancy is a common cause of abnormal uterine bleeding. The main causes of uterine bleeding can be fibroids in the uterus, infection of the cervix, and cancer of the uterus in some cases. Medications causing dysfunctional uterine bleeding are birth control pills, hormonal agents, and Coumadin.

Rising prevalence of uterine disorders such as uterine cancer, polycystic ovary syndrome, endometriosis, and uterine polyps drive the dysfunctional uterine bleeding market growth. Furthermore, rising prevalence of uterine cancer, and demand for diagnosis and treatment measures also influence the dysfunctional uterine bleeding market growth. According to the Cancer Research, in 2014, 9324 new cases of uterine cancer were diagnosed in U.K and the number is expected to increase in the near future.

According to the World Cancer Research Fund International, endometrial cancer is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012. It also stated that about 53% of endometrial cancer cases occurred in the developed countries.FIGURE 1: Global Dysfunctional Uterine Bleeding Market by Region, 2016 (%)

U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

 Key Players in the Dysfunctional Uterine Bleeding Market

Some of the key players in dysfunctional uterine bleeding market are B. Braun Melsungen AG (Germany), Hologic Inc. (U.S.), Karl Storz Gmbh & Co. KG (Germany), Medgyn Products, Inc., Olympus (Japan), Richard Wolf GmbH (Germany), Stryker (U.S.), Xion Medical GmbH (Germany), Cadila Pharmaceuticals Ltd. (India), Torrent Phamraceuticals (India).

Segments     

The dysfunctional uterine bleeding market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of type, dysfunctional uterine bleeding market is segmented into ovulatory, and anovulatory.

On the basis of diagnosis, the dysfunctional uterine bleeding market is segmented into hysteroscopy, ultrasonography, dilation and curettage, endometrial biopsy, and others.

On the basis of treatment, the dysfunctional uterine bleeding market is segmented into pharmacologic treatment, hysterectomy, endometrial ablation, and others. The pharmacologic treatment includes oral contraceptives, estrogen, progestins, desmopressin and others.

On the basis of end user, the dysfunctional uterine bleeding market is segmented into hospitals, clinics, diagnostic centers, pharmaceutical companies, and others.

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Regional Analysis of the Global Dysfunctional Uterine Bleeding Market   

America is the largest market for dysfunctional uterine bleeding market across the globe. The dysfunctional uterine bleeding market is driven by the rising prevalence of uterine cancer and other uterine disorders among women. According to the American Cancer Institute, about 61,380 new cases of uterine cancer is estimated to be diagnosed in 2017.

Europe is the second largest market owing to an increasing demand for diagnosis and treatment measures for uterine cancer, fibroids and other disorders, and increasing emphasis on women healthcare.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing prevalence of menstrual disorders, rising awareness about causes of such disorders and early diagnosis and treatment measures among women. The market is also driven by rising prevalence of sexually transmitted diseases among women in the developing nations.

The Middle East & Africa also show a steady rise in the market owing to increasing focus on women and child health, and need of primary care services in developing regions.

Intended Audience

• Drug Manufacturers


• Drug Suppliers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Report Scope: